Original-Research: NFON AG - from NuWays AG 13.11.2024 / 09:01 CET / CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.
13.11.2024 - 09:02:36Original-Research: NFON AG (von NuWays AG): Buy
Original-Research: NFON AG - from NuWays AG
13.11.2024 / 09:01 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS
Group AG.
The issuer is solely responsible for the content of this research. The
result of this research does not constitute investment advice or an
invitation to conclude certain stock exchange transactions.
---------------------------------------------------------------------------
Classification of NuWays AG to NFON AG
Company Name: NFON AG
ISIN: DE000A0N4N52
Reason for the research: Update
Recommendation: Buy
from: 13.11.2024
Target price: EUR 11.70
Target price on sight of: 12 months
Last rating change:
Analyst: Philipp Sennewald
Q3e: Further improving top-line & profitability, chg.
NFON will release Q3 figures on 21st November. Overall, we expect a solid
release including further sequential improvements on top- and bottom-line.
In detail:
Q3 sales are seen to increase 5.4% yoy to EUR 21.6m on the back of imposed
prices increases as well as continuous seat growth. Again, we expect an
increasing share of recurring revenues of 94.6%, implying recurring revenues
of EUR 20.4m. On the other hand, non-recurring hardware sales are seen to
remain muted in Q3 with EUR 1.2m. With this, we expect the ARPU to come in at
a solid level of EUR 9.94. Yet, we expect a further ARPU improvement going
forward, driven by (1) the up-selling of premium solutions as well as (2)
the consolidation of botario effective with Q4.
On this basis, Q3 adj. EBITDA is expected to come in at EUR 2.9m (+10.3% yoy),
implying a 13.3% margin. This should be partly driven by an improved gross
margin but mainly by the imposed efficiency measures in personnel (eNuW:
cost ratio down 1.9pp vs FY '23) and especially sales & marketing (eNuW:
other OpEx -1.7pp vs FY '23). Also, FCF should again come in strong with EUR
1.5m (eNuW). Against this backdrop, management should confirm the FY '24
guidance, targeting recurring revenue growth in the mid- to upper
single-digit range (eNuW: +5.3% yoy), adj. EBITDA of EUR 10-12m (eNuW: EUR
11.3m) as well as a recurring revenue ratio of 90+% (eNuW: 94.3%). This
should be easily achieved, in our view, given 9M '24e adj. EBITDA of EUR 8.5m
as well as sequentially improving recurring revenue growth so far in 2024.
Going forward, we expect the integration of DTS to offer further upside as
well as the consolidation of newly acquired AI-subsidiary botario. Here, we
also expect strong synergies to arise in the form of cross- and up-selling.
Overall, the company remains excellently positioned to grasp the highly
promising opportunities in the European market for integrated business
communication, in our view. As valuation remains attractive at 8.4x
EV/EBITDA '24e (5.5x '25e), wer reiterate BUY with an unchanged PT of EUR
11.70 based on DCF. NFON also remains one of our top-picks as part of the
NuWays Alphalist.
You can download the research here: http://www.more-ir.de/d/31297.pdf
For additional information visit our website: www.nuways-ag.com/research
Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss
bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben
analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++
---------------------------------------------------------------------------
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
---------------------------------------------------------------------------
2028591 13.11.2024 CET/CEST
